SCHEMBL31015574

SCHEMBL31015574

Nc1cncc(N2CC3CC3C2)n1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMPD3 Q9NY59 4/20 0.45
▸ MAP3K12 Q12852 1/20 0.37
▸ RBP4 P02753 1/20 0.37
▸ CDK2 P24941 1/20 0.36
▸ HRH3 Q9Y5N1 4/20 0.35
▸ KDM4E B2RXH2 1/20 0.32
▸ MEN1 O00255 1/20 0.32
▸ ALDH1A1 P00352 1/20 0.32
▸ CYP1A2 P05177 1/20 0.32
▸ CYP3A4 P08684 1/20 0.32
▸ HTR1A P08908 1/20 0.32
▸ CYP2C9 P11712 1/20 0.32
▸ HPGD P15428 1/20 0.32
▸ HTR2A P28223 1/20 0.32
▸ HTR2C P28335 1/20 0.32
▸ CYP2C19 P33261 1/20 0.32
▸ KMT2A Q03164 1/20 0.32
▸ HSD17B10 Q99714 1/20 0.32
▸ MAPK3 P27361 1/20 0.32
▸ MAPK1 P28482 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17609864 0.78 SMPD3 (0.38) SMPD3MAP3K12RBP4
SCHEMBL31015347 0.78 KDM4E (0.54) SMPD3RBP4CDK2KDM4EMEN1
SCHEMBL31015264 0.78 SMPD3 (0.39) SMPD3MAP3K12RBP4KDM4EMEN1
SCHEMBL22163202 0.74 SMPD3 (0.49) SMPD3MAP3K12HRH3MEN1CYP1A2
SCHEMBL23599609 0.73 SMN1; SMN2 (0.44) SMPD3CDK2KDM4EMEN1ALDH1A1
SCHEMBL17609917 0.73 MAP3K12 (0.43) SMPD3MAP3K12
SCHEMBL31066331 0.71 MAP3K12 (0.41) SMPD3MAP3K12HRH3
SCHEMBL245740 0.70 KMT2A (0.49) SMPD3MAP3K12MEN1CYP1A2KMT2A
SCHEMBL2640550 0.70 HRH4 (0.54) HRH3
SCHEMBL31014469 0.69 SMPD3 (0.34) SMPD3MAP3K12RBP4HCRTR1HCRTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250002475-A1 PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS EPICS THERAPEUTICS (BE) 2025-01-02 — — US disclosed
US-12091400-B2 Piperidine derivatives as METTL3 inhibitors EPICS THERAPEUTICS (BE) 2024-09-17 — — US disclosed
US-20240270716-A1 PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS EPICS THERAPEUTICS (BE) 2024-08-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240270716-A1 PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS METTL3, METTL16, DIMT1 SMPD3 1499/4885MAP3K12 4181/4885RBP4 1993/4885
US-20250002475-A1 PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS METTL3, METTL16, DIMT1 SMPD3 1499/4885MAP3K12 4181/4885RBP4 1993/4885
US-12091400-B2 Piperidine derivatives as METTL3 inhibitors METTL3, METTL16, DIMT1 SMPD3 1499/4885MAP3K12 4181/4885RBP4 1993/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback